[SCHEDULE 13G] Ascent Solar Technologies, Inc. SEC Filing

Rhea-AI Filing Summary

ProKidney Corp. (PROK) filed a Post-Effective Amendment No. 1 to its previously effective Form S-4 on 3 July 2025 to reflect the company’s completed domestication from the Cayman Islands to Delaware, which became effective 1 July 2025. The amendment, submitted under Rule 414(d), formally adopts the earlier Cayman Islands registration statement as the successor Delaware issuer’s own, avoiding any lapse in Securities Act or Exchange Act coverage.

Key points for investors:

• Corporate domicile change: The legal entity is now a Delaware corporation governed by the DGCL, its new certificate of incorporation and by-laws. Delaware’s well-established case law may enhance predictability around shareholder rights and M&A activity.
• Capital continuity: Every Class A and Class B ordinary share of the Cayman entity automatically converted 1-for-1 into the same class of Delaware common stock with identical proportional equity interests; no dilution or change in share count occurred.
• Listing & identifiers: Shares continue trading on Nasdaq Capital Market under ticker “PROK”; however, the CUSIP changed to 74291D 104.
• Management & operations unchanged: Business, assets, liabilities, fiscal year and the full board/executive team remain exactly the same post-domestication.
• Expert consents & exhibits: New opinions from Akin Gump (Ex. 5.1) and EY’s audit consent (Ex. 23.1) are filed; Delaware charter and by-laws are incorporated by reference.
• Indemnification framework: The filing details DGCL provisions and the company’s charter/by-law clauses that limit director & officer liability and permit broad indemnification, supplemented by D&O insurance and individual indemnification agreements.

No new securities are being offered and the amendment is largely administrative; it ensures continuous SEC registration and updates the governing law and disclosure cross-references to reflect the Delaware entity.

Positive

• Improved legal framework: Delaware incorporation offers clearer corporate governance standards and may broaden institutional investor appeal.
• No dilution risk: 1-for-1 conversion ensures shareholder ownership percentages remain unchanged post-domestication.

Negative

• None.

Insights

Corporate Governance Specialist

TL;DR — Re-domiciling to Delaware is administratively complex but strategically neutral-to-positive; no economic impact on shares.

Moving from the Cayman Islands to Delaware positions ProKidney within the U.S.’s most sophisticated corporate law regime. Investors often view Delaware charters as providing clearer fiduciary standards, efficient courts (Chancery Court) and greater deal certainty in potential M&A scenarios. The amendment confirms 1-for-1 share conversion, unchanged operations and board continuity, eliminating dilution concerns. Delaware permits officer exculpation and robust indemnification, which can aid director recruitment and reduce governance risk, but also slightly elevates the protective shield around management. No financial metrics shift, so valuation remains intact. Overall impact on shareholder value is modest yet directionally positive because of improved legal predictability and U.S. jurisdictional alignment.

Securities Analyst

TL;DR — Amendment keeps registration alive; ticker same, CUSIP new; fundamentally neutral to earnings outlook.

The POS AM merely restates the existing S-4 under the successor company’s name, ensuring SEC compliance after domestication. Because the share structure and Nasdaq listing are untouched, liquidity and index inclusion should be unaffected. The new CUSIP will automatically flow through broker/dealer back-offices; no action is required by retail or institutional holders. There are no new offerings, no fee table adjustments and no revisions to previously filed financials. From a capital-markets angle, the step is housekeeping with minimal direct valuation effect, though some U.S.-based funds with Cayman restrictions may now participate, providing a marginally broader investor base.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Ascent Solar Technologies, Inc.

(Name of Issuer)

Common stock, par value $0.0001 per share

(Title of Class of Securities)

043635804

(CUSIP Number)

06/27/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 043635804

1

Names of Reporting Persons

Mitchell P. Kopin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 317,830.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 209,636.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

317,830.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 043635804

1

Names of Reporting Persons

Daniel B. Asher

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 317,830.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 209,636.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

317,830.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 043635804

1

Names of Reporting Persons

Intracoastal Capital LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 317,830.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 209,636.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

317,830.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Ascent Solar Technologies, Inc.
(b)	Address of issuer's principal executive offices: 12300 Grant Street, Thornton, CO 80241
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
(b)	Address or principal business office or, if none, residence: The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.
(c)	Citizenship: Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
(d)	Title of class of securities: Common stock, par value $0.0001 per share
(e)	CUSIP No.: 043635804
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on June 27, 2025 (the "SPA") (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 30, 2025), each of the Reporting Persons may have been deemed to have beneficial ownership of 213,649 shares of Common Stock, which consisted of (i) 212,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (ii) 1,649 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 1"), and all such shares of Common Stock represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 1,924,980 shares of Common Stock outstanding prior to the execution of the SPA, as reported to the Reporting Persons by the Issuer, plus (2) 212,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (3) 1,649 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 286,351 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock, (II) 500,000 shares of Common Stock issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 2") because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock and (III) 17,361 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 3") because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,017,361 shares of Common Stock. (ii) As of the close of business on July 3, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of 317,830 shares of Common Stock, which consisted of (i) 109,000 shares of Common Stock held by Intracoastal and (ii) 208,830 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, and all such shares of Common Stock represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 2,177,658 shares of Common Stock outstanding as of June 27, 2025, as reported by the Issuer, plus (2) 507,000 shares of Common Stock issued at the closing of the transaction contemplated by the SPA, (3) 288,000 shares of Common Stock issued to Intracoastal upon exercise of Intracoastal Warrant 1 and (4) 208,830 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes (I) 291,170 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock and (II) 17,361 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3 because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 626,361 shares of Common Stock.
(b)	Percent of class: 9.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 317,830
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 209,636
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Mitchell P. Kopin

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin
Date:	07/03/2025

Daniel B. Asher

Signature:	/s/ Daniel B. Asher
Name/Title:	Daniel B. Asher
Date:	07/03/2025

Intracoastal Capital LLC

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin, Manager
Date:	07/03/2025

Exhibit Information

Exhibit 1 - Joint Filing Agreement

FAQ

Why did ProKidney (PROK) file a POS AM on July 3, 2025?

The amendment updates the existing S-4 to reflect ProKidney’s completed move from the Cayman Islands to Delaware and formally adopts the filing under the new entity.

Do PROK shareholders need to exchange their certificates after the domestication?

No. Each Cayman ordinary share automatically converted into an equivalent Delaware common share, so holders keep the same proportional interest without action.

Did the PROK ticker symbol or exchange listing change?

Ticker remains “PROK” on Nasdaq Capital Market; only the CUSIP changed to 74291D 104.

Are any new securities being offered in this filing?

No. The POS AM is administrative; it registers no additional shares and involves no capital raise.

Where can investors find the new Delaware charter and by-laws?

They are incorporated by reference as Exhibits 3.1 and 3.2 to the company’s Form 12B filed on July 3, 2025.

Does the redomestication impact ProKidney’s management or operations?

No. Business operations, assets, liabilities and the full board/executive team remain unchanged.